Success Metrics

Clinical Success Rate
75.0%

Based on 6 completed trials

Completion Rate
75%(6/8)
Active Trials
4(33%)
Results Posted
133%(8 trials)
Terminated
2(17%)

Phase Distribution

Ph not_applicable
1
8%
Ph phase_2
4
33%
Ph phase_1
4
33%
Ph phase_3
3
25%

Phase Distribution

4

Early Stage

4

Mid Stage

3

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
4(33.3%)
Phase 2Efficacy & side effects
4(33.3%)
Phase 3Large-scale testing
3(25.0%)
N/ANon-phased studies
1(8.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

75.0%

6 of 8 finished

Non-Completion Rate

25.0%

2 ended early

Currently Active

4

trials recruiting

Total Trials

12

all time

Status Distribution
Active(4)
Completed(6)
Terminated(2)

Detailed Status

Completed6
Recruiting3
Terminated2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
4
Success Rate
75.0%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (33.3%)
Phase 24 (33.3%)
Phase 33 (25.0%)
N/A1 (8.3%)

Trials by Status

recruiting325%
terminated217%
completed650%
active_not_recruiting18%

Recent Activity

4 active trials
Showing 5 of 12
recruitingphase_3

Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera

NCT06093672
recruitingphase_2

Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study

NCT03373968
recruitingphase_3

Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy

NCT05933057
active_not_recruitingphase_2

Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms

NCT01761968
completedphase_1

Givinostat and Metabolites Pharmacokinetics in Urine and Plasma (Part 3)

NCT05860114
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT06093672Phase 3

Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera

Recruiting
NCT03373968Phase 2

Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study

Recruiting
NCT05933057Phase 3

Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy

Recruiting
NCT01761968Phase 2

Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms

Active Not Recruiting
NCT05860114Phase 1

Givinostat and Metabolites Pharmacokinetics in Urine and Plasma (Part 3)

Completed
NCT03238235Phase 2

Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Becker Muscular Dystrophy

Completed
NCT05845567Phase 1

The Potential of Givinostat as DDI Victim in Co-administration P-gp Inhibitor (Part 2)

Completed
NCT01761292Phase 1

A Study to Assess Safety/Tolerability, pk, Effects on Histology, Clinical Parameters of Givinostat in Children With DMD

Completed
NCT02851797Phase 3

Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy

Completed
NCT01557452Not Applicable

Open-Label Extension of the Dose Finding Study (DSC/08/2357/36) in Patients With Poly Juvenile Idiopathic Arthritis

Terminated
NCT01901432Phase 1

A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Vera

Completed
NCT01261624Phase 2

Efficacy and Safety Dose Finding Study of Givinostat to Treat Polyarticular Course Juvenile Idiopathic Arthritis

Terminated

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12